PET/CT in Psoriatic Arthritis

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by University of Pennsylvania
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01654198
First received: July 27, 2012
Last updated: February 11, 2015
Last verified: July 2012
  Purpose

When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA). At this time, doctors use information from the history and physical exam to determine the diagnosis. X-rays, magnetic resonance imaging (MRI) and ultrasound have been used to help with the diagnosis but all three have limitations. A newer imaging technique, whole body Positron Emission Tomography/Computed Tomography (PET/CT) uses the idea that inflammatory cells take up sugar to locate inflammation in the body. Because patients with PsA have inflammatory cells in their joints and tendons, this type of scan allows the physician to take a picture of the whole body and locate inflammation. The investigators have found that some patients with psoriasis (but without arthritis) have inflammation in joints and tendons even before the patient has symptoms. In this study, the investigators will explore how well PET/CT works for assessing inflammation in patients with PsA. This would be a very exciting tool that could be used to find and treat inflammation before it causes damage or pain.


Condition Intervention
Psoriatic Arthritis
Radiation: FDG-PET/CT scan

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses. [ Time Frame: At the discretion of the PI ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP. [ Time Frame: At the discretion of the PI ] [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: July 2012
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Psoriatic arthritis Radiation: FDG-PET/CT scan
FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with psoriatic arthritis defined by CASPAR criteria and active joint disease.

Criteria

Inclusion Criteria:

  • Age 18-80,
  • active psoriatic arthritis (joint or enthesis inflammation)

Exclusion Criteria:

  • Diabetes,
  • pregnant,
  • no active PsA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01654198

Locations
United States, Pennsylvania
University of Pennsylvania Division of Rheumatology Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Alexis Ogdie-Beatty, MD    215-615-4375      
Principal Investigator: Alexis Ogdie-Beatty, MD, MSCE         
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Alexis R Ogdie, MD, MSCE University of Pennsylvania
  More Information

No publications provided

Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT01654198     History of Changes
Other Study ID Numbers: 815253
Study First Received: July 27, 2012
Last Updated: February 11, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Arthritis, Psoriatic
Arthritis
Bone Diseases
Joint Diseases
Musculoskeletal Diseases
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Spinal Diseases
Spondylarthritis
Spondylarthropathies
Spondylitis

ClinicalTrials.gov processed this record on September 03, 2015